Sinopharm Group Co Stock Gross Profit
| X2S Stock | 2.48 0.07 2.75% |
Sinopharm Group Co fundamentals help investors to digest information that contributes to Sinopharm Group's financial success or failures. It also enables traders to predict the movement of Sinopharm Stock. The fundamental analysis module provides a way to measure Sinopharm Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinopharm Group stock.
Sinopharm |
Sinopharm Group Co Company Gross Profit Analysis
Sinopharm Group's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Sinopharm Group Co reported 0.0 of gross profit. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Gross Profit (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Sinopharm Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is currently under evaluation in gross profit category among its peers.
Sinopharm Fundamentals
| Current Valuation | 15.96 B | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 0.11 X | |||
| Total Debt | 8.42 B | |||
| Price To Earnings To Growth | 49.43 X | |||
| Market Capitalization | 5.93 B | |||
| Total Asset | 335.41 B | |||
| Annual Yield | 0.29 % | |||
| Net Asset | 335.41 B |
About Sinopharm Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinopharm Group Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sinopharm Stock Analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.